Cargando…
SARS-CoV-2 screening in cancer outpatients during the second wave of the COVID-19 pandemic: Conclusions for crisis response at a high-volume oncology center
BACKGROUND: During the second wave of the coronavirus disease 2019 (COVID-19) pandemic Austria suffered one of the highest severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rates worldwide. We report performance parameters of a SARS-CoV‑2 screening program established for cancer outpatien...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375465/ https://www.ncbi.nlm.nih.gov/pubmed/34410467 http://dx.doi.org/10.1007/s00508-021-01927-7 |
_version_ | 1783740319464947712 |
---|---|
author | Berger, Julia M. Gansterer, Margaretha Trutschnig, Wolfgang Bathke, Arne C. Strassl, Robert Lamm, Wolfgang Raderer, Markus Preusser, Matthias Berghoff, Anna S. |
author_facet | Berger, Julia M. Gansterer, Margaretha Trutschnig, Wolfgang Bathke, Arne C. Strassl, Robert Lamm, Wolfgang Raderer, Markus Preusser, Matthias Berghoff, Anna S. |
author_sort | Berger, Julia M. |
collection | PubMed |
description | BACKGROUND: During the second wave of the coronavirus disease 2019 (COVID-19) pandemic Austria suffered one of the highest severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rates worldwide. We report performance parameters of a SARS-CoV‑2 screening program established for cancer outpatients at our center. METHODS: Institutional policy recommended routine biweekly SARS-CoV‑2 testing. Adherence to the testing recommendation during the second wave of the COVID-19 pandemic between 1 October and 30 November 2020 was analyzed. The SARS-CoV‑2 infection rate during first wave period (21 March to 4 May 2020) was compared to the one during second wave. RESULTS: A total of 1577 cancer patients were seen at our outpatient clinic during the second wave. In 1079/1577 (68.4%) patients, at least 1 SARS-CoV2 test was performed. Overall 2833 tests were performed, 23/1577 (1.5%, 95% confidence interval, CI 1.0–2.2%) patients were tested positive for SARS-CoV‑2, which indicates a significant increase compared to the first wave (4/1016; 0.4%, 95% CI 0.1–1.0%) with an odds ratio of 3.9 (95% CI 1.5–10.1; p < 0.005). Patients undergoing active anticancer treatment (172/960; 17.9% not tested) were more likely to have undergone a SARS-CoV‑2 test than patients in follow-up or best supportive care (326/617; 52.8% not tested p < 0.001). Furthermore, patients with only 1 visit within 4 weeks were more likely to not have undergone a SARS-CoV‑2 test (386/598; 64.5%) compared to patients with 2 or more visits (112/979; 11.4%; p < 0.001). The projected number of patients with undetected SARS-CoV‑2 infection during the study period was 5. CONCLUSION: We identified clinical patient parameters influencing SARS-CoV‑2 testing coverage in cancer outpatients. Our data can provide information on generation of standard operating procedures and resource allocation during subsequent infection waves. |
format | Online Article Text |
id | pubmed-8375465 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Vienna |
record_format | MEDLINE/PubMed |
spelling | pubmed-83754652021-08-20 SARS-CoV-2 screening in cancer outpatients during the second wave of the COVID-19 pandemic: Conclusions for crisis response at a high-volume oncology center Berger, Julia M. Gansterer, Margaretha Trutschnig, Wolfgang Bathke, Arne C. Strassl, Robert Lamm, Wolfgang Raderer, Markus Preusser, Matthias Berghoff, Anna S. Wien Klin Wochenschr Original Article BACKGROUND: During the second wave of the coronavirus disease 2019 (COVID-19) pandemic Austria suffered one of the highest severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rates worldwide. We report performance parameters of a SARS-CoV‑2 screening program established for cancer outpatients at our center. METHODS: Institutional policy recommended routine biweekly SARS-CoV‑2 testing. Adherence to the testing recommendation during the second wave of the COVID-19 pandemic between 1 October and 30 November 2020 was analyzed. The SARS-CoV‑2 infection rate during first wave period (21 March to 4 May 2020) was compared to the one during second wave. RESULTS: A total of 1577 cancer patients were seen at our outpatient clinic during the second wave. In 1079/1577 (68.4%) patients, at least 1 SARS-CoV2 test was performed. Overall 2833 tests were performed, 23/1577 (1.5%, 95% confidence interval, CI 1.0–2.2%) patients were tested positive for SARS-CoV‑2, which indicates a significant increase compared to the first wave (4/1016; 0.4%, 95% CI 0.1–1.0%) with an odds ratio of 3.9 (95% CI 1.5–10.1; p < 0.005). Patients undergoing active anticancer treatment (172/960; 17.9% not tested) were more likely to have undergone a SARS-CoV‑2 test than patients in follow-up or best supportive care (326/617; 52.8% not tested p < 0.001). Furthermore, patients with only 1 visit within 4 weeks were more likely to not have undergone a SARS-CoV‑2 test (386/598; 64.5%) compared to patients with 2 or more visits (112/979; 11.4%; p < 0.001). The projected number of patients with undetected SARS-CoV‑2 infection during the study period was 5. CONCLUSION: We identified clinical patient parameters influencing SARS-CoV‑2 testing coverage in cancer outpatients. Our data can provide information on generation of standard operating procedures and resource allocation during subsequent infection waves. Springer Vienna 2021-08-19 2021 /pmc/articles/PMC8375465/ /pubmed/34410467 http://dx.doi.org/10.1007/s00508-021-01927-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Berger, Julia M. Gansterer, Margaretha Trutschnig, Wolfgang Bathke, Arne C. Strassl, Robert Lamm, Wolfgang Raderer, Markus Preusser, Matthias Berghoff, Anna S. SARS-CoV-2 screening in cancer outpatients during the second wave of the COVID-19 pandemic: Conclusions for crisis response at a high-volume oncology center |
title | SARS-CoV-2 screening in cancer outpatients during the second wave of the COVID-19 pandemic: Conclusions for crisis response at a high-volume oncology center |
title_full | SARS-CoV-2 screening in cancer outpatients during the second wave of the COVID-19 pandemic: Conclusions for crisis response at a high-volume oncology center |
title_fullStr | SARS-CoV-2 screening in cancer outpatients during the second wave of the COVID-19 pandemic: Conclusions for crisis response at a high-volume oncology center |
title_full_unstemmed | SARS-CoV-2 screening in cancer outpatients during the second wave of the COVID-19 pandemic: Conclusions for crisis response at a high-volume oncology center |
title_short | SARS-CoV-2 screening in cancer outpatients during the second wave of the COVID-19 pandemic: Conclusions for crisis response at a high-volume oncology center |
title_sort | sars-cov-2 screening in cancer outpatients during the second wave of the covid-19 pandemic: conclusions for crisis response at a high-volume oncology center |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375465/ https://www.ncbi.nlm.nih.gov/pubmed/34410467 http://dx.doi.org/10.1007/s00508-021-01927-7 |
work_keys_str_mv | AT bergerjuliam sarscov2screeningincanceroutpatientsduringthesecondwaveofthecovid19pandemicconclusionsforcrisisresponseatahighvolumeoncologycenter AT gansterermargaretha sarscov2screeningincanceroutpatientsduringthesecondwaveofthecovid19pandemicconclusionsforcrisisresponseatahighvolumeoncologycenter AT trutschnigwolfgang sarscov2screeningincanceroutpatientsduringthesecondwaveofthecovid19pandemicconclusionsforcrisisresponseatahighvolumeoncologycenter AT bathkearnec sarscov2screeningincanceroutpatientsduringthesecondwaveofthecovid19pandemicconclusionsforcrisisresponseatahighvolumeoncologycenter AT strasslrobert sarscov2screeningincanceroutpatientsduringthesecondwaveofthecovid19pandemicconclusionsforcrisisresponseatahighvolumeoncologycenter AT lammwolfgang sarscov2screeningincanceroutpatientsduringthesecondwaveofthecovid19pandemicconclusionsforcrisisresponseatahighvolumeoncologycenter AT raderermarkus sarscov2screeningincanceroutpatientsduringthesecondwaveofthecovid19pandemicconclusionsforcrisisresponseatahighvolumeoncologycenter AT preussermatthias sarscov2screeningincanceroutpatientsduringthesecondwaveofthecovid19pandemicconclusionsforcrisisresponseatahighvolumeoncologycenter AT berghoffannas sarscov2screeningincanceroutpatientsduringthesecondwaveofthecovid19pandemicconclusionsforcrisisresponseatahighvolumeoncologycenter |